Pediatric Blood & Cancer · 2020 · 33 citations · 29 references
MedicineOncologySurgeryCell TherapyRegenerative MedicineStem Cell TransplantationAutologous Stem Cell TransplantationCancer Stem CellsTransplant SurvivalApheresis ProcessingAutologous Stem Cell InfusionAutologous Stem Cell TherapyAutologous Transplant ConditioningInpatient Admission RatesSurvival After Autologous TransplantationTherapeutic Apheresis
BACKGROUND: The majority of patients in low- and middle-income countries (LMIC) are unable to receive optimal therapy, including autologous stem cell transplant (ASCT) for high-risk neuroblastoma. Management is intensive and multidisciplinary; survival is often poor. We report a single-center outcome of high-risk neuroblastoma, with adaptations optimized for LMIC. PROCEDURE: The study was retrospective. Patients were treated on the backbone of the high-risk neuroblastoma study-1 of SIOP-Europe (HR-NBL1/SIOPEN) protocol with ASCT. Adaptations incorporated to decrease cost, requirement for inpatient admission, infections, and faster engraftment included (a) optional outpatient administration for rapid-COJEC, (b) two sessions of stem-cell apheresis, (c) storing stem cells at 2-6°C without cryopreservation for up to 7 days, (d) no central lines, (e) no antibacterial/antifungal/antiviral prophylaxis, (f) omitting formal assessment of cardiac/renal/pulmonary functions before ASCT, and (g) administration of pegylated granulocyte colony-stimulating factor on Day +4. RESULTS: Over 5 years 9 months, 35 patients with high-risk neuroblastoma were treated. Rapid-COJEC was administered over a median duration of 80 days (interquartile range: 77, 83). Conditioning regimen included melphalan (n = 7), oral busulfan-melphalan (Bu/Mel; n = 6), or intravenous Bu/Mel (n = 22). The median viability of stem cells stored for 6 days (n = 28) was 93% (range: 88-99). Two (5.7%) patients had ASCT-related mortality. The 3-year overall and event-free survival was 41% and 39%, respectively. A relapse occurred in 20 (57%) patients. Treatment abandonment was observed in one (3%) patient. CONCLUSIONS: Administration of therapy in a disciplined time frame along with low-cost adaptations enables to manage high-risk neuroblastoma with low abandonment and an encouraging survival in LMIC. Stem cells can be stored safely without cryopreservation for up to 7 days.
29
Katherine K. Matthay, Judith G. Villablanca, Robert C. Seeger et al. · New England Journal of Medicine · 1999 · 1.9K citations · Full text
Medicine, Oncology, Pharmacology +7
Katherine K. Matthay, C. Patrick Reynolds, Robert C. Seeger et al. · Journal of Clinical Oncology · 2009 · 856 citations
Medicine, Oncology, Chemotherapy +6
Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text
Medicine, Oncology, Pharmacology +8